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Stavudine dosage reduction: Effect on 
symptomatic hyperlactataemia and lactic 
acidosis in patients at Dr George Mukhari 
Hospital, Pretoria
To the Editor: A range of studies have demonstrated that 
symptomatic hyperlactataemia and lactic acidosis are associated 
with antiretroviral combinations containing stavudine.[1,2] The 
HIV treatment programme in Khayelitsha, Cape Town, which 
began using stavudine as a first-line therapy in 2003, reported 
approximately 10% of patients switching from stavudine to the 
alternative drug after 12 months due to hyperlactataemia.[3] 
Following a meta-analysis showing that lower doses of stavudine 
are safer and as effective, the World Health Organization (WHO) 
issued a statement that only a low dose of stavudine (30 mg) 
should be used.[4] 
This retrospective review included patients treated at the 
adult HIV clinic at Dr George Mukhari Hospital, Pretoria, 
South Africa. The study was approved by the Medunsa Research 
Ethics Committee (reference MP 156/2005). The records of 86 
patients (aged 27 - 59 years) initiated on stavudine-containing 
antiretroviral therapy regimens between 2004 and 2006 were 
analysed: 66 females (29 received 40 mg stavudine; 37 received 
30 mg stavudine) and 20 males (7 received 40 mg stavudine; 
13 received 30 mg stavudine). Lactate levels were not routinely 
determined for all patients (only when a clinician suspected 
lactic acidosis or symptomatic hyperlactataemia on the basis 
of clinical symptoms). A serum lactate level >2.0 mmol/l 
was considered to be elevated. Lactic acidosis was defined 
by persistently increased blood lactate levels (>5 mmol/l) in 
association with acidosis (pH <7.35) and a bicarbonate level 
≤ 20 mmol/l.[5]
Among female patients, elevated lactate levels developed 
in 18/29 (62%) treated with 40 mg stavudine, but only 13/37 
(35%) treated with 30 mg of stavudine (range 2.3 - 9.8 mmol/l). 
Among male patients, elevated lactate levels developed in 2/14 
(14%) treated with 30 mg stavudine and 2/7 (29%) treated with 
40 mg stavudine. 
Thirty-five patients (41%) had elevated lactate levels with 
signs or symptoms that obliged clinicians to cease treatment. 
The relative odds of developing elevated lactate levels when 
commencing treatment were 2.92 times higher in the group 
receiving 40 mg stavudine than in the group receiving 30 mg 
stavudine (95% confidence interval 1.10 - 2.51). The relative 
risk (RR) ratio was higher for female patients, with a greater 
risk for developing hyperlactataemia than males (RR 2.17 for 
40 mg stavudine; RR 2.28 for 30 mg stavudine) (Table 1). 
The onset of the first symptoms of elevated lactate levels 
occurred from 2 to 18 months following treatment initiation. 
Of the 35 patients with elevated lactate levels, 43% (n=15) were 
obese and 4 (11%) died due to complications of lactic acidosis. 
This analysis demonstrated that stavudine dose reduction 
increased the odds of patients being more stable on treatment 
with fewer reported side-effects. Stavudine-containing 
regimens should be avoided in obese female patients. Low-
dose stavudine (20 mg) may offer alternative solutions in poor 
or resource-limited settings, with  a lower associated risk of 
toxicity and side-effects; however, virological non-inferiority 
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Table 1.  Elevated lactate level in patients receiving 30 mg or 40 mg stavudine
40 mg stavudine 30 mg stavudine OR (95% CI)
Female, n (%) 3.02 (1.10 - 8.29)
Elevated lactate levels 18 (27) 13 (20)
Normal lactate levels 11 (17) 24 (36)
Total 29 (44) 37 (56)
Male, n (%) 2.20 (0.24 - 20.00)
Elevated lactate levels 2 (10) 2 (10)
Normal lactate levels 5 (25) 11 (55)
Total 7 (35) 13 (65)
OR = Odds ratio; CI = confidence interval.
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